Retrospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Mar 21, 2015; 21(11): 3300-3307
Published online Mar 21, 2015. doi: 10.3748/wjg.v21.i11.3300
Table 1 Patient characteristics n (%)
HepatectomyRFAP
n = 102n = 51
Sex (M/F)73/2935/160.71
Age (years) median (range)60 (3-79)58.5 (35-79)0.99
Preoperative CEA (ng/mL) median (range)4.4 (0.1-202)6.5 (0.9-144)0.19
Size of liver metastases, median (range)1.7 (0.2-3.0)1.8 (1.0-3.0)0.26
Number of liver metastasis
Single63 (62)29 (57)0.56
Multiple39 (38)22 (43)
Metastasis type
Synchronous76 (75)33 (65)0.21
Metachronous26 (25)18 (35)
Location of liver metastasis
Unilobal80 (78)38 (75)0.59
Bilobal22 (22)13 (25)
N stage
N030 (29)13 (25)0.61
N1, N272 (71)38 (75)
Location of primary colorectal cancer
Colon53 (52)29 (57)0.57
Rectum49 (48)22 (43)
Histological differentiation1
High grade88 (86)45 (88)0.73
Low grade14 (14)6 (12)
Comorbidity
Liver cirrhosis25 (5)6 (12)0.18
Diabetes mellitus20 (20)13 (25)0.40
Hypertension29 (28)12 (24)0.52
Cardiovascular disease3 (3)1 (2)0.72
Pulmonary disease6 (6)2 (4)0.99
Neoadjuvant chemotherapy
Yes6 (6)5 (10)0.30
No70 (94)28 (90)
Adjuvant chemotherapy
Yes95 (93)46 (90)0.54
No7 (7)5 (10)
Table 2 Disease-free survival after surgical treatment with curative intent for colorectal liver metastasis by multivariate analysis by Cox regression proportional hazard model (n = 153)
FactorsUnivariate analysis of DFSMultivariate analysis of DFS
PHR95%CIP1
Radiofrequency ablation0.0331.571.02-2.410.040
Female sex0.890
Age0.270
CEA (ng/mL)0.1301.030.99-1.010.480
Size (cm)0.210
Multiple0.1401.010.65-1.570.970
Metachronous0.0890.750.45-1.240.260
Bilobal0.300
T220.1300.550.18-1.650.290
T320.0900.780.41-1.490.450
Lymph node metastasis0.0031.941.14-3.310.015
Adjuvant chemotherapy0.810
Poorly differentiated grade0.0331.791.01-3.180.049